The prognostic significance of the alterations of pulmonary hemodynamics in patients with pulmonary arterial hypertension: a meta-regression analysis of randomized controlled trials

被引:7
|
作者
Sung, Shih-Hsien [1 ,2 ]
Yeh, Wan-Yu [3 ]
Chiang, Chern-En [2 ,4 ]
Huang, Chi-Jung [3 ]
Huang, Wei-Ming [1 ,2 ]
Chen, Chen-Huan [2 ,5 ,6 ,7 ]
Cheng, Hao-Min [2 ,3 ,5 ,6 ,7 ]
机构
[1] Taipei Vet Gen Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan
[2] Natl Yang Ming Chiao Tung Univ, Sch Med, Dept Med, Taipei, Taiwan
[3] Taipei Vet Gen Hosp, Ctr Evidence Based Med, 201,Sec 2,Shih Pai Rd, Taipei, Taiwan
[4] Taipei Vet Gen Hosp, Gen Clin Res Ctr, Taipei, Taiwan
[5] Natl Yang Ming Chiao Tung Univ, Inst Publ Hlth, Sch Med, Taipei, Taiwan
[6] Natl Yang Ming Chiao Tung Univ, Community Med Res Ctr, Sch Med, Taipei, Taiwan
[7] Taipei Vet Gen Hosp, Dept Med Educ, Taipei, Taiwan
关键词
Pulmonary arterial hypertension; Hemodynamics; Meta-regression; Meta-analysis; ENDOTHELIN-RECEPTOR ANTAGONIST; DOUBLE-BLIND; PROSTACYCLIN ANALOG; INHALED ILOPROST; THERAPY; SILDENAFIL; SURVIVAL; BOSENTAN; METAANALYSIS; MANAGEMENT;
D O I
10.1186/s13643-021-01816-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Hemodynamic assessment in patients with pulmonary arterial hypertension (PAH) is essential for risk stratification and pharmacological management. However, the prognostic value of the hemodynamic changes after treatment is less well established. Objectives We investigated the prognostic impacts of the changes in hemodynamic indices, including mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), right atrial pressure (RAP), and cardiac output index (CI). We conducted this systematic review with meta-regression analysis on existing clinical trials. Methods We searched and identified all relevant randomized controlled trials from multiple databases. An analogous R-2 index was used to quantify the proportion of variance explained by each predictor in the association with PAH patients' prognosis. A total of 21 trials and 3306 individuals were enrolled. Results The changes in mPAP, PVR, RAP, and CI were all significantly associated with the change in 6MWD ( increment 6MWD). The change in mPAP was with the highest explanatory power for increment 6MWD (R-2 analog = 0.740). Additionally, the changes in mPAP, PVR, and CI were independently predictive of adverse clinical events. The change in mPAP had the highest explanatory power for the clinical events (R-2 analog = 0.911). Furthermore, the change in PVR was with the highest explanatory power for total mortality of PAH patients (R-2 analog = 0.612). Conclusion Hemodynamic changes after treatment, including mPAP, PVR, CI, and RAP, were significantly associated with adverse clinical events or mortality in treated PAH patients. It is recommended that further studies be conducted to evaluate the changes in hemodynamic indices to guide drug titration. Systematic review registration PROSPERO
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Efficacy evaluation of pulmonary hypertension therapy in patients with portal pulmonary hypertension: A systematic review and meta-analysis
    Zhang, Ruihua
    Li, Tengfei
    Shao, Yueming
    Bai, Wei
    Wen, Xiaoyu
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [22] Efficacy and safety of pulmonary vasodilators in the patients with Eisenmenger syndrome: a meta-analysis of randomized controlled trials
    Hou, Yulin
    Wen, Li
    Shu, Tingting
    Dai, Rong
    Huang, Wei
    PULMONARY CIRCULATION, 2021, 11 (02)
  • [23] Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis
    Hoeper, Marius M.
    Pausch, Christine
    Olsson, Karen M.
    Huscher, Doerte
    Pittrow, David
    Gruenig, Ekkehard
    Staehler, Gerd
    Vizza, Carmine Dario
    Gall, Henning
    Distler, Oliver
    Opitz, Christian
    Gibbs, J. Simon R.
    Delcroix, Marion
    Ghofrani, H. Ardeschir
    Ewert, Ralf
    Kaemmerer, Harald
    Kabitz, Hans-Joachim
    Skowasch, Dirk
    Behr, Juergen
    Milger, Katrin
    Halank, Michael
    Wilkens, Heinrike
    Seyfarth, Hans-Juergen
    Held, Matthias
    Dumitrescu, Daniel
    Tsangaris, Iraklis
    Vonk-Noordegraaf, Anton
    Ulrich, Silvia
    Klose, Hans
    Claussen, Martin
    Eisenmann, Stephan
    Schmidt, Kai-Helge
    Rosenkranz, Stephan
    Lange, Tobias J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (07) : 971 - 981
  • [24] Exercise Training in Patients with Chronic Thromboembolic Pulmonary Hypertension and Pulmonary Arterial Hypertension A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Vanaken, Gabriella
    Rubick, Drew
    Wieczorek, Daniel
    Chatterjee, Saurav
    Moles, Victor M.
    Agarwal, Prachi P.
    Haft, Jonathan W.
    Cascino, Thomas M.
    Visovatti, Scott H.
    Aggarwal, Vikas
    HEART FAILURE CLINICS, 2025, 21 (01) : 137 - 148
  • [25] Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials
    Zhang, Qingyou
    Xu, Bowen
    Lv, Jichen
    Wang, Zhijian
    Du, Junbao
    CARDIOLOGY IN THE YOUNG, 2020, 30 (12) : 1882 - 1889
  • [26] Prostanoid therapy for pulmonary arterial hypertension: a meta-analysis of survival outcomes
    Zheng, Yaguo
    Yang, Tao
    Chen, Guo
    Hu, Enci
    Gu, Qing
    Xiong, Changming
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (01) : 13 - 21
  • [27] Exercise Hemodynamics in the Prognosis of Patients with Pulmonary Arterial Hypertension
    Faure, Morgane
    Valentin, Simon
    Zysman, Maeva
    Sitbon, Olivier
    Peretti, Laura
    Guillaumot, Anne
    Gomez, Emmanuel
    Huttin, Olivier
    Selton-Suty, Christine
    Chabot, Francois
    Chaouat, Ari
    RESPIRATION, 2020, 99 (08) : 678 - 685
  • [28] A Network Meta-analysis of the Efficacy and Safety of Targeted Drug Combinations in the Treatment of Pulmonary Arterial Hypertension
    Wang, Rui
    Wei, Meng
    Wang, Jie
    Huang, Xiang
    Yan, Qianzhi
    Wang, Shichao
    Wu, Yun
    CARDIOLOGY DISCOVERY, 2023, 3 (04): : 249 - 260
  • [29] Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension
    Al-Naamani, Nadine
    Palevsky, Harold I.
    Lederer, David J.
    Horn, Evelyn M.
    Mathai, Stephen C.
    Roberts, Kari E.
    Tracy, Russell P.
    Hassoun, Paul M.
    Girgis, Reda E.
    Shimbo, Daichi
    Post, Wendy S.
    Kawut, Steven M.
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2016, 13 (01) : 25 - 30
  • [30] Efficacy and Safety of Oral Treprostinil Monotherapy for the Treatment of Pulmonary Arterial Hypertension A Randomized, Controlled Trial
    Jing, Zhi-Cheng
    Parikh, Keyur
    Pulido, Tomas
    Jerjes-Sanchez, Carlos
    White, R. James
    Allen, Roblee
    Torbicki, Adam
    Xu, Kai-Feng
    Yehle, David
    Laliberte, Kevin
    Arneson, Carl
    Rubin, Lewis J.
    CIRCULATION, 2013, 127 (05) : 624 - 633